Oasmia presses ahead with new water-soluble paclitaxel formulation

The US FDA has granted orphan drug designation for Oasmia Pharmaceutical's Paclical (paclitaxel) for the treatment of ovarian cancer. The Swedish company hopes to achieve a 35% market share, its CEO, Julian Aleksov, told Scrip.